The window of therapeutic opportunity in multiple sclerosis: Evidence from monoclonal antibody therapy

Journal of Neurology

Volumn 253, Issue 1, 2006, Pages 98-108

  Coles, Alasdair J ^d   Cox, Amanda ^d   Le Page, Emmanuelle ^d   Jones, Joanne ^d   Trip, S Anand ^a   Deans, Jackie ^d   Seaman, Shaun ^b   Miller, David H ^a   Hale, Geoff ^c   Waldmann, Herman ^c   Compston, D Alastair ^d  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MRC BIOSTATISTICS UNIT   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Campath 1H; Cerebral atrophy; Multiple sclerosis

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BRAIN ATROPHY; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMPARATIVE STUDY; CONTROLLED STUDY; COURSE EVALUATION; DEMYELINATING DISEASE; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; NERVE CELL DEGENERATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL DISABILITY; PRIORITY JOURNAL; RELAPSE; SAMPLE SIZE; T CELL DEPLETION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIRHEUMATIC AGENTS; AUTOIMMUNITY; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISABILITY EVALUATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS; RECURRENCE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 31544467633     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-005-0934-5     Document Type: Article

References (67)

1. Annunziata P, Lore F, Venturini E, Morana P, Guarino E, Borghi S, Guazzi GC (1999) Early synthesis and correlation of serum anti-thyroid antibodies with clinical parameters in multiple sclerosis. J Neurol Sci 168:32-36
2. Bechtold DA, Kapoor R, Smith KJ (2004) Axonal protection using flecainide in experimental autoimmune encephalomyelitis. Ann Neurol 55:607-616
3. Brady ST, Witt AS, Kirkpatrick LL, de Waegh SM, Readhead C, Tu PH, Lee VM (1999) Formation of compact myelin is required for maturation of the axonal cytoskeleton. J Neurosci 19:7278-7288
4. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH (2002) A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 346:158-164
5. Broadley SA, Deans J, Sawcer SJ, Clayton D, Compston DA (2000) Autoimmune disease in first-degree relatives of patients with multiple sclerosis. A UK survey. Brain 123:1102-1111
6. Chard DT, Brex PA, Ciccarelli O, Griffin CM, Parker GJ, Dalton C, Altmann DR, Thompson AJ, Miller DH (2003) The longitudinal relation between brain lesion load and atrophy in multiple sclerosis: a 14 year follow up study. J Neurol Neurosurg Psychiatry 74:1551-1554
7. Colello RJ, Pott U, Schwab ME (1994) The role of oligodendrocytes and myelin on axon maturation in the developing rat retinofugal pathway. J Neurosci 14:2594-2605
8. Coles AJ, Paolillo A, Molyneux PD, Wing M, Hale G, Miller DH, Waldmann H, Compston DA (1998) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 44:464
9. Coles AJ, Wing M, Molyneux P, Paolillo A, Davie C, Hale G, Miller DH, Waldmann H, Compston A (1999) Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol 46:296-304
10. Coles AJ, Wing MG, Smith S, Corradu F, Greer S, Taylor CJ, Weetman AP, Hale G, Chatterjee KC, Waldmann H, Compston A (1999) Pulsed monoclonal antibody treatment and thyroid autoimmunity in multiple sclerosis. Lancet 354:1691-1695
11. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P, Sorensen PS, Rovaris M, Martinelli V, Hommes OR (2001) Effect of early Interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576-1582
12. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O, Hartung H, Seeldrayers P, Sorensen PS, Rovaris M, Martinelli V, Hommes OR (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357:1576-1582
13. Compston A, Coles A (2002) Multiple sclerosis. Lancet 359:1221-1231
14. Confavreux C, Vukusic S, Moreau T, Adeleine P (2000) Relapses and progression of disability in multiple sclerosis. N Engl J Med 343:1430-1438
15. Confavreux C, Vukusic S, Adeleine P (2003) Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 126:770-782
16. Cox AL, Thompson S, Hale G, Waldmann H, Compston DA, Coles AJ (2003) Lymphocyte depletion in multiple sclerosis induces a relative increase in regulatory T cells. Immunology 110, s1:81
17. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, McDonald WI (1994) Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 117:49-58
18. Durelli L, Ferrero B, Oggero A, Verdun E, Ghezzi A, Montanari E, Zaffaroni M (2001) Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS. Neurology 57:1363-1370
19. Durelli L, Oggero A, Verdun E, Isoardo GL, Barbero P, Bergamasco B, Brossa PC, Ghigo E, Maccario M, Faggiano F (2001) Thyroid function and antithyroid antibodies in MS patients screened for interferon treatment. A multicenter study. J Neurol Sci 193:17-22
20. Ferguson B, Matyszak MK, Esiri MM, Perry VH (1997) Axonal damage in acute multiple sclerosis lesions. Brain 120:393-399
21. Filippi M, Rovaris M, Iannucci G, Mennea S, Sormani MP, Comi G (2000) Whole brain volume changes in patients with progressive MS treated with cladribine. Neurology 55:1714-1718
22. Gilleece MH, Dexter TM (1993) Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 82:807-812
23. Golde S, Chandran S, Brown GC, Compston A (2002) Different pathways for iNOS-mediated toxicity in vitro dependent on neuronal maturation and NMDA receptor expression. J Neurochem 82:269-282
24. Griffiths I, Klugmann M, Anderson T, Yool D, Thomson C, Schwab MH, Schneider A, Zimmermann F, McCulloch M, Nadon N, Nave KA (1998) Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 280:1610-1613
25. Hale G, Waldmann H (1996) Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection. Bone Marrow Transpl 17:305-308
26. Hartung HP, Gonsette R, Konig N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T (2002) Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 360:2018-2025
27. Heesen C, Gbadamosi J, Schoser BG, Pohlau D (2001) Autoimmune hyperthyroidism in multiple sclerosis under treatment with glatiramer acetate - a case report. Eur J Neurol 8:199
28. Heinzlef O, Alamowitch S, Sazdovitch V, Chillet P, Joutel A, Tournier-Lasserve E, Roullet E (2000) Autoimmune diseases in families of French patients with multiple sclerosis. Acta Neurol Scand 101:36-40
29. Henderson RD, Saltissi D, Pender MP (1998) Goodpasture's syndrome associated with multiple sclerosis. Acta Neurol Scand 98:134-135
30. Ioppoli C, Meucci G, Mariotti S, Martino E, Lippi A, Gironelli L, Pinchera A, Muratorio A (1990) Circulating thyroid and gastric parietal cell autoantibodies in patients with multiple sclerosis. Ital J Neurol Sci 11:31-36
31. 3. Br J Ophthalmol 79:1054-1055
32. Isaacs JD, Hazleman BL, Chakravarty K, Grant JW, Hale G, Waldmann H (1996) Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H. J Rheumatol 23:1103-1106
33. Isaacs JD, Manna VK, Rapson N, Bulpitt KJ, Hazleman BL, Matteson EL, St. Clair EW, Schnitzer TJ, Johnston JM (1996) CAMPATH-1H in rheumatoid arthritis-an intravenous dose-ranging study. Br J Rheumatol 35:231-240
34. Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP, Waldmann H (1992) Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340:748-752
35. Kaplan MR, Meyer Franke A, Lambert S, Bennett V, Duncan ID, Levinson SR, Barres BA (1997) Induction of sodium channel clustering by oligodendrocytes. Nature 386:724-728
36. Kapoor R, Davies M, Blaker PA, Hall SM, Smith KJ (2003) Blockers of sodium and calcium entry protect axons from nitric oxide-mediated degeneration. Ann Neurol 53:174-180
37. Killick SB, Marsh JC, Hale G, Waldmann H, Kelly SJ, Gordon Smith EC (1997) Sustained remission of severe resistant autoimmune neutropenia with Campath-1H. Br J Haematol 97:306-308
38. Kotter MR, Zhao C, van Rooijen N, Franklin RJ (2005) Macrophage-depletion induced impairment of experimental CNS remyelination is associated with a reduced oligodendrocyte progenitor cell response and altered growth factor expression. Neurobiol Dis 18:166-175
39. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W (2002) Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125:2202-2212
40. Leary SM, Miller DH, Stevenson VL, Brex PA, Chard DT, Thompson AJ (2003) Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 60:44-51
41. Lim SH, Hale G, Marcus RE, Waldmann H, Baglin TP (1993) CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura. Br J Haematol 84:542-544
42. Lockwood CM, Thiru S, Stewart S, Hale G, Isaacs J, Wraight P, Elliott J, Waldmann H (1996) Treatment of refractory Wegener's granulomatosis with humanized monoclonal antibodies. QJM 89:903-912
43. Losseff NA, Wang L, Lai HM, Yoo DS, Gawne Cain ML, McDonald WI, Miller DH, Thompson AJ (1996) Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain 119:2009-2019
44. Matthews JN, Altman DG, Campbell MJ, Royston P (1990) Analysis of serial measurements in medical research. BMJ 300:230-235
45. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
46. Meyer Franke A, Kaplan MR, Pfrieger FW, Barres BA (1995) Characterization of the signaling interactions that promote the survival and growth of developing retinal ganglion cells in culture. Neuron 15:805-819
47. Miller DH, Molyneux PD, Barker GJ, MacManus DG, Moseley IF, Wagner K (1999) Effect of interferon-beta1b on magnetic resonance imaging outcomes in secondary progressive multiple sclerosis: results of a European multicenter, randomized, double-blind, placebo-controlled trial. European Study Group on Interferon-beta1b in secondary progressive multiple sclerosis. Ann Neurol 46:850-859
48. Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, Yousry T, Hahn D, Wagner K, Ghazi M, Beckmann K, Dahlke F, Losseff N, Barker GJ, Thompson AJ, Miller DH (2000) The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. Brain 123:2256-2263
49. Monzani F, Caraccio N, Meucci G, Lombardo F, Moscato G, Casolaro A, Ferdeghini M, Murri L, Ferrannini E (1999) Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patients with multiple sclerosis. Eur J Endocrinol 141:325-331
50. Moreau T, Thorpe J, Miller D, Moseley I, Hale G, Waldmann H, Clayton D, Wing M, Scolding N, Compston A (1994) Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis [published erratum appears in Lancet 1994 Aug 13,344(8920):486]. Lancet 344:298-301
51. Nicholas RS, Compston A, Brown DR (2001) Inhibition of tumour necrosis factor-alpha (TNFalpha)-induced NF-kappaB p52 converts the metabolic effects of microglial-derived TNFalpha on mouse cerebellar neurones to neurotoxicity. J Neurochem 76:1431-1438
52. Paolillo A, Coles AJ, Molyneux P, Gawne Cain ML, MacManus D, Barker GJ, Compston A, Miller D (1999) Quantitative MRI in patients with secondary progressive multiple sclerosis treated with monoclonal antibody Campath-1H. Neurology 53:751-757
53. Redford EJ, Kapoor R, Smith KJ (1997) Nitric oxide donors reversibly block axonal conduction: demyelinated axons are especially susceptible. Brain 120:2149-2157
54. Rice GP, Filippi M, Comi G (2000) Cladribine and progressive MS: clinical and MRI outcomes of a multicenter controlled trial. Cladribine MRI Study Group. Neurology 54:1145-1155
55. Riechmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332:323-327
56. Rotondi M, Oliviero A, Profice P, Mone CM, Biondi B, Del Buono A, Mazziotti G, Sinisi AM, Bellastella A, Carella C (1998) Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis. J Endocrinol Invest 21:748-752
57. Sanchez I, Hassinger L, Paskevich PA, Shine HD, Nixon RA (1996) Oligodendroglia regulate the regional expansion of axon caliber and local accumulation of neurofilaments during development independently of myelin formation. J Neurosci 16:5095-5105
58. Simon JH, Jacobs L, Kinkel RP (2001) Transcallosal bands: a sign of neuronal tract degeneration in early MS? Neurology 57:1888-1890
59. Simon JH, Jacobs L, Kinkel RP (2001) Transcallosal bands: a sign of neuronal tract degeneration in early MS? Neurology 57:1888-1890
60. Smith KJ, Kapoor R, Hall SM, Davies M (2001) Electrically active axons degenerate when exposed to nitric oxide. Ann Neurol 49:470-476
61. Stadelmann C, Kerschensteiner M, Misgeld T, Bruck W, Hohlfeld R, Lassmann H (2002) BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 125:75-85
62. The CHAMPS Study Group (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343:898-904
63. Trapp BD, Peterson J, Ransohoff RM, Rudick RA, Mork S, Bo L (1998) Axonal transection in the lesions of multiple sclerosis. N Engl J Med 338:278-285
64. Verdun E, Isoardo G, Oggero A, Ferrero B, Ghezzi A, Montanari E, Zaffaroni M, Durelli L (2002) Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases? J Interferon Cytokine Res 22:245-255
65. Weinshenker BG, Bass B, Rice GP, Noseworthy J, Carriere W, Baskerville J, Ebers GC (1989) The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain 112:1419-1428
66. Wilkins A, Chandran S, Compston A (2001) A role for oligodendrocyte- derived IGF-1 in trophic support of cortical neurons. Glia 36:48-57
67. Wilkins A, Majed H, Layfield R, Compston A, Chandran S (2003) Oligodendrocytes promote neuronal survival and axonal length by distinct intracellular mechanisms: a novel role for oligodendrocyte-derived glial cell line-derived neurotrophic factor. J Neurosci 23:4967-4974